Department of Nephrology, Xiangya Hospital, Central South University, Changsha, Hunan, PR China.
School of Biological Sciences, University of Western Australia, Perth, Australia.
Cell Immunol. 2019 Jun;340:103878. doi: 10.1016/j.cellimm.2018.11.002. Epub 2018 Nov 7.
Casitas B lymphoma-b (Cbl-b), a RING finger E3 ubiquitin ligase, has been identified as a critical regulator of adaptive immune responses. Cbl-b is essential for establishing the threshold for T cell activation and regulating peripheral T cell tolerance through various mechanisms. Intriguingly, recent studies indicate that Cbl-b also modulates innate immune responses, and plays a key role in host defense to pathogens and anti-tumor immunity. These studies suggest that targeting Cbl-b may represent a potential therapeutic strategy for the management of human immune-related disorders such as autoimmune diseases, infections, tumors, and allergic airway inflammation. In this review, we summarize the latest developments regarding the roles of Cbl-b in innate and adaptive immunity, and immune-mediated diseases.
卡斯蒂亚斯 B 淋巴瘤-b（Cbl-b），一种 RING 指 E3 泛素连接酶，已被确定为适应性免疫反应的关键调节因子。Cbl-b 对于建立 T 细胞激活的阈值以及通过各种机制调节外周 T 细胞耐受至关重要。有趣的是，最近的研究表明 Cbl-b 还调节先天免疫反应，并在宿主防御病原体和抗肿瘤免疫中发挥关键作用。这些研究表明，靶向 Cbl-b 可能代表管理人类免疫相关疾病（如自身免疫性疾病、感染、肿瘤和过敏性气道炎症）的一种潜在治疗策略。在这篇综述中，我们总结了 Cbl-b 在先天和适应性免疫以及免疫介导的疾病中的最新作用。
